Limits...
Hurdles and delays in access to anti-cancer drugs in Europe.

Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R, Piccart M, Parent F - Ecancermedicalscience (2014)

Bottom Line: Developing an anticancer drug and bringing it into clinical practice is, therefore, a lengthy and complex process involving multiple partners in several areas.To optimize patient treatment and increase the likelihood of implementing health innovation, it is essential to have an overview of the full process.This review aims to describe the process and discuss the hurdles arising at each step.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels 1000, Belgium.

ABSTRACT
Demographic changes in the world population will cause a significant increase in the number of new cases of cancer. To handle this challenge, societies will need to adapt how they approach cancer prevention and treatment, with changes to the development and uptake of innovative anticancer drugs playing an important role. However, there are obstacles to implementing innovative drugs in clinical practice. Prior to being incorporated into daily practice, the drug must obtain regulatory and reimbursement approval, succeed in changing the prescription habits of physicians, and ultimately gain the compliance of individual patients. Developing an anticancer drug and bringing it into clinical practice is, therefore, a lengthy and complex process involving multiple partners in several areas. To optimize patient treatment and increase the likelihood of implementing health innovation, it is essential to have an overview of the full process. This review aims to describe the process and discuss the hurdles arising at each step.

No MeSH data available.


Related in: MedlinePlus

Drug flux from the pharmaceutical company to the patient.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4263523&req=5

figure3: Drug flux from the pharmaceutical company to the patient.

Mentions: The uptake level of any drug is also closely linked to the percentage of governmental reimbursement and patient co-payment. In the case of no-reimbursement, competition, or significant patient co-payment, uptake is generally lower. Figure 3 depicts the flow of drugs from pharmaceutical companies to the patient.


Hurdles and delays in access to anti-cancer drugs in Europe.

Ades F, Zardavas D, Senterre C, de Azambuja E, Eniu A, Popescu R, Piccart M, Parent F - Ecancermedicalscience (2014)

Drug flux from the pharmaceutical company to the patient.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4263523&req=5

figure3: Drug flux from the pharmaceutical company to the patient.
Mentions: The uptake level of any drug is also closely linked to the percentage of governmental reimbursement and patient co-payment. In the case of no-reimbursement, competition, or significant patient co-payment, uptake is generally lower. Figure 3 depicts the flow of drugs from pharmaceutical companies to the patient.

Bottom Line: Developing an anticancer drug and bringing it into clinical practice is, therefore, a lengthy and complex process involving multiple partners in several areas.To optimize patient treatment and increase the likelihood of implementing health innovation, it is essential to have an overview of the full process.This review aims to describe the process and discuss the hurdles arising at each step.

View Article: PubMed Central - PubMed

Affiliation: Department of Medical Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels 1000, Belgium.

ABSTRACT
Demographic changes in the world population will cause a significant increase in the number of new cases of cancer. To handle this challenge, societies will need to adapt how they approach cancer prevention and treatment, with changes to the development and uptake of innovative anticancer drugs playing an important role. However, there are obstacles to implementing innovative drugs in clinical practice. Prior to being incorporated into daily practice, the drug must obtain regulatory and reimbursement approval, succeed in changing the prescription habits of physicians, and ultimately gain the compliance of individual patients. Developing an anticancer drug and bringing it into clinical practice is, therefore, a lengthy and complex process involving multiple partners in several areas. To optimize patient treatment and increase the likelihood of implementing health innovation, it is essential to have an overview of the full process. This review aims to describe the process and discuss the hurdles arising at each step.

No MeSH data available.


Related in: MedlinePlus